Publications by authors named "G S Chernin"
Hemodialysis patients are susceptible to excess volume accumulation, particularly over the 2-day interval (long interdialytic gap), resulting in higher interdialytic weight gain (IDWG). We thought to determine whether a novel device designed to enhance fluid and salt loss by activating the eccrine sweat glands can mitigate IDWG. Patients eligible for the study were undergoing regular hemodialysis for ≥3 months, without residual renal function, and with IDWG (as a percentage of IDWG/dry body weight) ≥2.
View Article and Find Full Text PDFArticle Synopsis
- The FLOW trial investigated the effects of semaglutide on cardiovascular (CV) events and death in individuals with type 2 diabetes and chronic kidney disease (CKD).
- Results showed that semaglutide lowered the risk of CV death, non-fatal heart attacks, and strokes by 18%, and overall mortality by 20% across various levels of CKD severity.
- The beneficial effects of semaglutide were consistent regardless of kidney function, protein levels in urine, or risk classification.
Aims: Dapagliflozin was approved for use in patients with chronic kidney disease (CKD) based on results of the DAPA-CKD trial, demonstrating attenuation of CKD progression and reduced risk of cardio-renal outcomes and all-cause mortality (ACM) versus placebo, in addition to standard therapy. The study objective was to assess the potential medical care cost offsets associated with reduced rates of cardio-renal outcomes across 31 countries and regions.
Materials And Methods: A comparative cost-determination framework estimated outcome-related costs of dapagliflozin plus standard therapy versus standard therapy alone over a 3-year horizon based on the DAPA-CKD trial.
Article Synopsis
- Diabetes mellitus (DM) increases the likelihood of neointimal hyperplasia (NIH) and restenosis after percutaneous coronary intervention (PCI), prompting a study to assess the link between DM severity and NIH after PCI.
- The study involved patients with DM from the BLADE-PCI trial, focusing on those with recent HbA1c levels; results indicated that patients with uncontrolled DM (HbA1c ≥ 7.5%) had a higher mean percentage of NIH volume compared to those with controlled DM (HbA1c < 7.5%).
- Despite these findings, no significant association was observed between higher HbA1c levels and increased NIH risk, leading to the conclusion that uncontrolled DM at PCI does